Sanofi Genzyme

Sanofi Genzyme. It is the specialty care global business unit of the French multinational pharmaceutical corporation Sanofi. Originally founded as the independent biotechnology firm Genzyme in Boston, the unit is renowned for pioneering treatments for rare diseases, particularly lysosomal storage disorders. Its integration into Sanofi following a major acquisition in 2011 created one of the world's leading entities focused on orphan drugs and biologics.

History

The company's origins trace back to 1981 when scientists including Henry E. Blair and Sheridan Snyder founded Genzyme in Boston. Its early work focused on biologic tools and diagnostics, but a strategic shift toward therapeutic development was catalyzed by the 1991 FDA approval of Ceredase (alglucerase), the first treatment for Gaucher disease. This established Genzyme as a leader in enzyme replacement therapy. The company expanded globally, opening manufacturing facilities in Ireland and Framingham, Massachusetts, and pursued acquisitions like that of BioMarin Pharmaceutical's Aldurazyme rights. In 2011, after a protracted hostile takeover battle, Sanofi successfully acquired Genzyme for over $20 billion, subsequently rebranding the division as Sanofi Genzyme.

Products and therapies

Sanofi Genzyme's portfolio is anchored in treatments for rare diseases and specialized conditions. Its flagship products include Cerezyme (imiglucerase) and Elelyso (taliglucerase alfa) for Gaucher disease, and Fabrazyme (agalsidase beta) for Fabry disease. The division also markets Myozyme and Lumizyme (alglucosidase alfa) for Pompe disease and Aldurazyme (laronidase) for Mucopolysaccharidosis I. Beyond metabolic disease, it commercializes significant therapies for multiple sclerosis, such as Aubagio (teriflunomide) and Lemtrada (alemtuzumab). Additional areas include oncology with Jevtana (cabazitaxel) and immunology with Kevzara (sarilumab), developed in partnership with Regeneron Pharmaceuticals.

Research and development

The division's R&D strategy is heavily focused on advancing therapies for orphan diseases and complex conditions. Key research hubs are located in Cambridge, Massachusetts, and Lyon, France, leveraging expertise in genetics, immunology, and protein engineering. Major pipelines include next-generation enzyme replacement therapies, gene therapy approaches for disorders like Hemophilia A, and investigational treatments for multiple sclerosis and amyotrophic lateral sclerosis. Sanofi Genzyme collaborates extensively with academic institutions like Harvard University and biotech firms, including a long-standing alliance with Alnylam Pharmaceuticals on RNA interference therapeutics. Its work often involves navigating the FDA's Orphan Drug Act and European Medicines Agency regulatory pathways.

Corporate affairs

As a core unit of Sanofi, Sanofi Genzyme operates with considerable autonomy in its specialty care focus. Its global headquarters remains in Cambridge, Massachusetts, a key node in the Boston biotechnology cluster. The division manages an extensive global supply chain, with critical manufacturing sites in Waterford, Ireland, and Geel, Belgium, for biologics. It engages in significant patient assistance programs and advocacy group partnerships, such as with the National Gaucher Foundation, to support access to its high-cost therapies. Leadership has included notable figures from both the legacy Genzyme and parent Sanofi organizations, integrating the cultures of a pioneering biotech and a global pharmaceutical industry giant.

Controversies and legal issues

The division has faced several significant challenges. A major manufacturing crisis occurred in 2009 when viral contamination forced the prolonged shutdown of its Allston Landing plant in Boston, creating severe shortages of Cerezyme and Fabrazyme, leading to patient rationing and drawing scrutiny from the FDA. Sanofi later faced litigation and a $19.5 million settlement with the U.S. Department of Justice over allegations that the legacy Genzyme violated the False Claims Act by promoting Seprafilm for unapproved uses. Furthermore, its drug Lemtrada encountered initial rejections from the FDA over safety concerns and has been the subject of ongoing pharmacovigilance monitoring for serious adverse effects like autoimmune conditions.

Category:Sanofi Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Pharmaceutical companies established in 1981